Upside Options Positioning in AstraZeneca (AZN) Continues -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
AstraZeneca (AZN) Granted Breakthrough Therapy Designation by U.S. FDA for Tagrisso (Osimertinib)
October 9, 2017 9:19 AM EDTAstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for TAGRISSO® (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: The Breakthrough Designation acknowledges not only TAGRISSOs potential as a 1st-line standard of care in advanced EGFR mutation-positive NSCLC, but also the significant need for improved clinical outcomes in this disease. The results of the FLAURA trial have the potential to redefine clinical... More
AstraZeneca (AZN) Says EMA Accepted MAA for Imfinzi in Locally-Advanced Unresectable NSCLC
October 9, 2017 6:24 AM EDTAstraZeneca (NYSE: AZN), along with MedImmune, its global biologics research and development arm, has announced that the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Imfinzi(durvalumab) for the treatment of patients with locally-advanced (Stage III), unresectable non-small cell... More
Catalan parliament defies Madrid pressure, works on independence declaration
October 6, 2017 5:28 AM EDTBy Sam Edwards and Raquel Castillo
BARCELONA/MADRID (Reuters) - Catalan secessionists were working on Friday toward a unilateral declaration of independence from Spain that could be adopted next week in defiance of a court order and increased economic pressure from Madrid.
After Spain's Constitutional Court suspended a session of the Catalan regional parliament set for Monday, which had been expected to endorse an independence declaration, the parliament said the region's pro-independence leader Carles Puigdemont would address the assembly at 6 p.m. (1600 GMT) on Tuesday.
Madrid apologized for the first time on Friday for police... More
